Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Participate in the Canaccord Genuity 41st Annual Growth Conference

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a...
August 02, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold Second Quarter 2021 Financial Results Conference Call on Monday, August 9, 2021

MOUNTAIN VIEW, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2021 financial results will be released after market...
July 06, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis

SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an...
June 16, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Participate in the Raymond James 2021 Human Health Innovations Conference

SAN CARLOS, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a...
June 08, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Abstract on Avacopan in ANCA-Associated Vasculitis Selected as One of the Ten Best Abstracts at the ERA-EDTA Congress

-- Abstract on ‘The Effect of Avacopan, a Complement C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis with Renal Disease’ honored on “Ten Best” list by the Paper...
May 06, 2021 23:37 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Announces Results of FDA Advisory Committee Meeting on Avacopan in ANCA-Associated Vasculitis

SAN CARLOS, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the outcome of the U.S. Food and Drug Administration (“FDA”) Arthritis Advisory Committee...
April 29, 2021 16:05 ET | Source: ChemoCentryx, Inc.

ChemoCentryx Reports First Quarter 2021 Financial Results and Recent Highlights

-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee...
April 22, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Hold First Quarter 2021 Financial Results Conference Call on Thursday, April 29, 2021

MOUNTAIN VIEW, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2021 financial results will be released after market...
April 09, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx’s Oral PD-L1 inhibitor, CCX559, Featured in Poster Presentation at the 2021 American Association for Cancer Research (AACR) Annual Meeting

-- CCX559 enhanced primary human T cell activity in vitro and demonstrated anti-tumor efficacy in two murine tumor models -- -- Company plans to advance CCX559 into clinical development in the...
April 07, 2021 08:30 ET | Source: ChemoCentryx, Inc.

ChemoCentryx to Host Virtual R&D Day on April 14, 2021

MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30...